spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  kidney cancer 

 HSMN NewsFeed - 14 Jun 2021
Jim Vasselli, M.D., Joins Aulos Bioscience as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 14 May 2021
Rigel Appoints Alison L. Hannah, M.D. to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Aug 2019
Boston Scientific Closes Acquisition of BTG plc.
Devices Interventional Oncology Mergers & Acquisitions
 HSMN NewsFeed - 27 Jun 2019
OncoSec Receives Exclusive Licensing Rights from Dana-Farber Cancer Institute to CAR T-Cell Therapies for the Treatment of Solid Tumor Cancers
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 20 Mar 2019
IceCure Medical Presents Promising Results from First-ever Interventional Radiology Study With Its Next Generation Liquid Nitrogen (LN2) Cryoablation System, ProSense(TM)
Devices Oncology Interventional
 HSMN NewsFeed - 20 Nov 2018
Boston Scientific Announces Recommended Offer to Acquire BTG plc.
Devices Interventional Oncology Mergers & Acquisitions
 HSMN NewsFeed - 23 Jun 2017
EUSA Pharma Receives Positive CHMP Opinion for Tivozanib for the First-Line Treatment of Advanced Renal Cell Carcinoma in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 9 Jan 2017
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 10 Oct 2016
First Positive Phase 3 Results in Adjuvant Setting for Renal Cell Carcinoma Show SUTENT(R) (sunitinib) Extended Disease Free Survival After Surgical Removal
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Sep 2016
European Commission Approves CABOMETYX(TM) (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Jul 2016
David Meek appointed as Chief Executive Officer of Ipsen
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Aug 2014
FDA Approves Genentech’s Avastin Plus Chemotherapy for Treatment of Advanced Cervical Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Jun 2014
Curis Announces Executive Management Transition
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 12 Mar 2014
Rosetta Genomics Provides Product Pipeline Update
Diagnostics
 HSMN NewsFeed - 18 Feb 2014
Rosetta Genomics Appoints Kevin Watson as Director, Reimbursement-Managed Care
Diagnostics Oncology Reimbursement Personnel
 HSMN NewsFeed - 7 Nov 2013
Surefire Medical Closes Series B Funding at $18.2 Million
Devices Oncology Venture Capital
 HSMN NewsFeed - 21 Feb 2013
SynCardia Total Artificial Heart Patient with End-Stage Renal Failure Recovers Kidney Function after Two Months of Support
Devices Cardiology
 HSMN NewsFeed - 31 Oct 2012
Stereotactic Radiosurgery Shows Promise for Kidney Cancer
Devices Oncology
 HSMN NewsFeed - 17 Sep 2012
Pfizer To Present New Data in Lung And Kidney Cancers at The European Society For Medical Oncology 2012 Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Sep 2012
Pfizer Receives EU Marketing Authorization for INLYTA(R) (Axitinib)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 10 Aug 2012
Pfizer Reports Results From Phase 3 Study Of Torisel (temsirolimus) In Combination With Bevacizumab In Advanced Renal Cell Carcinoma (RCC)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Jul 2012
Delcath Announced Changes To Board Of Directors
Devices Drug Delivery Oncology Personnel
 HSMN NewsFeed - 22 May 2012
Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 May 2012
Galena Biopharma Announces Expansion of Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Jan 2012
U.S. Food And Drug Administration Approves Pfizer’s INLYTA(R) (axitinib) For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Oct 2011
Onyx Pharmaceuticals and Bayer Healthcare Restructure Global Oncology Partnership
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jul 2011
Phase III Trial of Novartis Drug Afinitor(R) Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Biopharmaceuticals
 HSMN NewsFeed - 20 May 2011
SUTENT(R) Receives U.S. FDA Approval For Advanced Pancreatic Neuroendocrine Tumors
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 May 2011
Prometheus Obtains Exclusive US Commercialization Rights for RENCAREX(R)
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 24 Feb 2011
FDA Grants Genentech a Hearing on Avastin’s Use for Metastatic Breast Cancer in the United States
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Feb 2011
Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Feb 2011
Third Phase III Study of Avastin-Based Regimen Met Primary Endpoint in Ovarian Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Dec 2010
Genentech Provides Update on Avastin for Metastatic Breast Cancer Following Reviews in Europe and the United States
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Dec 2010
Study Shows Novartis Drug Afinitor(R) Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Nov 2010
Study in NEJM Shows Novartis Drug Afinitor(R) Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Oct 2010
Novartis Drug Afinitor(R) Approved by FDA as First Medication for Children and Adults with a Benign Brain Tumor Associated with Tuberous Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 7 Oct 2010
Onyx Pharmaceuticals Provides Status Update on Carfilzomib
Biopharmaceuticals
 HSMN NewsFeed - 13 Sep 2010
AVEO Pharmaceuticals, Inc. Appoints Michael P. Bailey to the Newly Created Position of Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Sep 2010
Onyx Pharmaceuticals Announces Carfilzomib Development and Commercialization Agreement with Ono Pharmaceutical for Japan
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Jun 2010
Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Mar 2010
EDAP Presents Ablatherm-HIFU Data in Localized Prostate Cancer at Third Focal Therapy Symposium
Devices Oncology
 HSMN NewsFeed - 26 Jan 2010
Prometheus Acquires Exclusive Rights to PROLEUKIN(R) (aldesleukin) in the U.S.
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 22 Jan 2010
Data Show Progression-Free Survival Advantage with Sutent(R) in Patients with Pancreatic Neuroendocrine Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Oct 2009
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Patients With Non-Responsive Thyroid Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Oct 2009
Antigenics Announces a Negative Vote From the CHMP on Oncophage(R) Marketing Application in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 12 Oct 2009
Proteolix, Inc. to be Acquired By Onyx Pharmaceuticals
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 12 Oct 2009
Onyx Pharmaceuticals to Acquire Proteolix, Inc.
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 5 Oct 2009
GlaxoSmithKline Receives Unanimous FDA Panel Approval Recommendation for VOTRIENT(TM)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Sep 2009
Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Sep 2009
Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Aug 2009
Patients Begin Enrolling into Investigator-Sponsored Phase 2 Trial of Antigenics' Oncophage(R) Cancer Vaccine in Newly Diagnosed Glioma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Aug 2009
FDA Approves Avastin for the Most Common Type of Kidney Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Jul 2009
Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2009
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 May 2009
Nexavar Approved in Japan for the Treatment of Advanced Liver Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 29 Apr 2009
FDA Grants Orphan Drug Designation to Oncophage for the Treatment of Glioma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Feb 2009
Pfizer's Sutent is Recommended as First-Line Treatment for Kidney Cancer Patients by British Health Agency
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 29 Sep 2008
FDA Grants Permission For Export of Antigenics' Oncophage(R) to Russia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Sep 2008
Is Cost Containment Impacting Pharmaceutical Innovation?
Biopharmaceuticals Reimbursement
 HSMN NewsFeed - 15 Aug 2008
Onyx Pharmaceuticals Names Juergen Lasowski, Ph.D. as Senior Vice President of Corporate Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Jul 2008
Nexavar Approved for Liver Cancer in China
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 Jul 2008
FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions
Biopharmaceuticals Radiology FDA
 HSMN NewsFeed - 2 Jun 2008
Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2008
NCCN Previews Chemotherapy Order Templates(TM)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 May 2008
RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 May 2008
Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Apr 2008
Pfizer Japan Receives Manufacturing and Marketing Authorization for SUTENT
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 Apr 2008
Oncophage(R) Approved in Russia for the Treatment of Intermediate-Risk Kidney Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 13 Mar 2008
Sequence of Treatments May Induce Clinical Response in Metastatic Renal Cell Carcinoma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Mar 2008
Misonix CEO Announces HIFU Strategy Targeting Cancer Therapy
Devices Oncology
 HSMN NewsFeed - 28 Feb 2008
Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Feb 2008
Onyx Pharmaceuticals Names N. Anthony Coles, M.D. as President, Chief Executive Officer and Member of its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Feb 2008
New Breakthrough Treatment for Advanced Kidney Cancer Shows 49 Per Cent Higher Survival Rates
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Feb 2008
Bayer and Onyx Provide Update on Phase 3 Trial of Nexavar in Patients With Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Feb 2008
CyberKnife Users' Meeting Highlights Major Clinical Data Milestones and Emerging Trends
Devices Oncology
 HSMN NewsFeed - 19 Dec 2007
Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Nov 2007
Wyeth's TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 19 Nov 2007
Nexavar First FDA-Approved Drug Therapy for Liver Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Oct 2007
Nexavar Becomes First and Only Approved Treatment of Hepatocellular Carcinoma in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 25 Oct 2007
Data from Investigator-Sponsored Trial of Oncophage(R) Cancer Vaccine in Glioma Presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Oct 2007
New Study Data Published in British Journal of Urology Demonstrates Cryoablation Effective for Kidney Cancer
Devices Oncology
 HSMN NewsFeed - 4 Oct 2007
Onyx Pharmaceuticals Announces Management Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Sep 2007
Nexavar Receives Positive Opinion from European Committee for Medicinal Products for Human Use for Treatment of Liver Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Sep 2007
European Committee Issues Positive Opinion on Wyeth's TORISEL(TM) for Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 13 Sep 2007
Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
Biopharmacetuicals Personnel
 HSMN NewsFeed - 27 Aug 2007
Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Aug 2007
Nexavar Granted FDA Priority Review for Treatment of Liver Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Aug 2007
Misonix Highlights Recent Duke University Study Revealing Significant New Cancer Treatment May Be Possible with HIFU Technology
Devices Oncology
 HSMN NewsFeed - 2 Aug 2007
Hollis-Eden Pharmaceuticals Names Scott M. Freeman, M.D., Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Aug 2007
Antigenics Provides Update on Filing for Approval of Oncophage(R) in Russia for the Treatment of Intermediate-Risk Kidney Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Aug 2007
NCCN Updates Kidney Cancer Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Jul 2007
Agensys Raises $41 Million
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 27 Jun 2007
Bayer and Onyx Submit Supplemental New Drug Application for Nexavar to Treat Liver Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Jun 2007
Pfizer's Lyrica Receives FDA Approval for Fibromyalgia Based on Expedited Review
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Jun 2007
Bayer and Onyx Submit New European Marketing Authorization Application to EMEA for Nexavar to Treat Liver Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 4 Jun 2007
Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Single-Agent SUTENT Prolonged Progression-Free Survival across All Advanced Kidney Cancer Patient Risk Groups, Including Those with Poorest Prognoses, Data Show
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Oxford Biomedica and Sanofi-Aventis Report new TroVax(R) Phase II Trial Results in Renal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Phase III Study Shows Avastin Plus Interferon Therapy Nearly Doubled Median Progression-Free Survival in Patients With Previously Untreated Advanced Kidney Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Data Presented at ASCO Showed TORISEL Significantly Increased Quality-Adjusted Survival for Patients With Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2007
FDA Approves TORISEL, a Targeted First-in-Class mTOR Inhibitor for the Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 May 2007
Data Published in the New England Journal of Medicine Showed TORISEL Extended Median Overall Survival for Patients with Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 May 2007
Rexahn Pharmaceuticals Receives FDA Approval to Initiate a Phase II Trial for Archexin in Patients with Renal Cell Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 May 2007
Oncophage(R) Cancer Vaccine Significantly Prolongs Recurrence-Free Survival by 45 Percent in Patients With Intermediate-Risk Kidney Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 May 2007
BIO Urges Congress to Prioritize Patient Safety and Biomedical Innovation in Pathway for Follow-On Biologics
Biopharmaceuticals
 HSMN NewsFeed - 6 Apr 2007
Wyeth Provides Update on FDA Review of the Torisel New Drug Application
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Apr 2007
Bayer Healthcare Pharmaceuticals Officially Launches in the United States
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 13 Feb 2007
Pfizer's Maraviroc to Receive Accelerated Regulatory Reviews in the U.S. and Europe
Biopharmaceuticals Regulatory HIV/AIDS
 HSMN NewsFeed - 12 Feb 2007
Nexavar Shown to Significantly Extend Survival for Patients with Advanced Liver Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Feb 2007
Pfizer's Sutent Receives FDA Approval to Include New First-Line Advanced Kidney Cancer Data in Label
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Jan 2007
Bayer and Onyx Announce Pivotal Nexavar(R) Kidney Cancer Study Published in New England Journal of Medicine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Dec 2006
New England Journal of Medicine Publishes Data from Pivotal Study of Avastin Plus Chemotherapy in Most Common Type of Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Dec 2006
Interim Analysis of Phase III Trial Shows Avastin Plus Interferon Therapy Improved Progression-Free Survival in Patients With Previously Untreated Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Dec 2006
Elron Announces Completion by Galil Medical Of $52 Million Financing and Acquisition of Oncura's Urology Related Cryotherapy Business
Devices Mergers & Acquisitions
 HSMN NewsFeed - 4 Dec 2006
Phase III Trial of Nexavar in Patients with Advanced Melanoma Does Not Meet Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Nov 2006
Galil Medical, an Elron Group Company, Announces Term Sheet for New Financing of $40 Million
Devices Venture Capital
 HSMN NewsFeed - 22 Nov 2006
Galil Medical, an Elron Group Company, in Advanced Negotiations to Sell Its Interest in Oncura and to Acquire Oncura's Urology Related Cryotherapy Business
Devices Urology
 HSMN NewsFeed - 7 Nov 2006
Cleveland Clinic Unveils 'Top 10' Medical Innovations for 2007
Devices Biopharmaceuticals Cardiology Oncology Neurology
 HSMN NewsFeed - 12 Oct 2006
Agennix Receives FDA Orphan Drug Designation for Talactoferrin Alfa in Renal Cell Carcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Oct 2006
FDA Approves Avastin(R) in Combination With Chemotherapy for First-Line Treatment of Most Common Type of Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Oct 2006
Wyeth Submits NDA and MAA for Torisel for the Treatment of Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Jul 2006
Nexavar(R) Approved by European Commission for the Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Jul 2006
James L. Freddo, M.D., Joins Anadys Pharmaceuticals as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 May 2006
Misonix Reports: Influential Urologists From Around the World Speak of the Benefits of the Sonablate(R) 500 at the 6th Annual SB500 User Group Meeting at the AUA Conference
Devices Oncology Urology
 HSMN NewsFeed - 24 May 2006
26 Cryoablation Studies Presented at National Urological Meeting
Devices Oncology Urology
 HSMN NewsFeed - 22 May 2006
Prostate-Specific Membrane Antigen (PSMA) Expression in Neovasculature Associated with Renal Cell Carcinoma is Characterized
Diagnostics Oncology Urology
 HSMN NewsFeed - 18 May 2006
Geron Names Laurence Elias, M.D., Vice President, Oncology Clinical Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 May 2006
Pfizer's Smoking Cessation Medicine Chantix(TM) (Varenicline) Receives FDA Approval
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 85

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 85 additional stories matching:
kidney cancer
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.